NRAS and neoplasm: Regardless of whether cell lines had common driver mutations (ie, KRAS) or less frequently occurring mutations (ie, BRAF, NRAS) or a combination of mutated genes, treatment with motesanib as monotherapy or in combination with chemotherapy resulted in tumor growth inhibition, albeit at different doses depending on the model.